Loading…
CLINDAMYCIN is a brand name for Clindamycin. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: Antibacterial. Serious infections caused by susceptible Gram-positive organisms, staphylococci (both penicillinase- and non-penicillinase-producing), streptococci (except Streptococcus faecalis) and pneumococci. It is also indicated in serious infections caused by susceptible anaerobic pathogens. Clindamycin does not…
Verbatim from this product's MHRA label. Tap a section to expand.
Posology Adults:
Moderately severe infection, 150 - 300 mg every six hours; severe infection, 300 - 450 mg every six hours.
Elderly patients:
The half-life, volume of distribution and clearance, and extent of absorption after administration of clindamycin hydrochloride are not altered by increased age. Analysis of data from clinical studies has not revealed any age-related increase in toxicity.
Dosage requirements in elderly patients, therefore, should not be influenced by age alone. Paediatric population: 3 - 6 mg/kg every six hours depending on the severity of the infection.
Dosage in Renal/Hepatic Impairment:
Clindamycin dosage modification is not necessary in patients with renal or hepatic insufficiency.
Note:
In cases of beta-haemolytic streptococcal infection, treatment with Clindamycin Capsules should continue for at least 10 days to diminish the likelihood of subsequent rheumatic fever or glomerulonephritis. Method of administration Oral.
Clindamycin Capsules should always be taken with a full glass of water. Absorption of Clindamycin Capsules is not appreciably modified by the presence of food.
The table below lists the adverse reactions identified through clinical trial experience and post-marketing surveillance by system organ class and frequency. Adverse reactions identified from post-marketing experience are included in italics.
The frequency grouping is defined using the following convention:
Very common (≥1/10); Common (≥ 1/100 to <1/10); Uncommon (≥1/1,000 to <1/100); Rare (≥ 1/10,000 to <1/1,000); Very Rare (< 1/10,000); and Not known (cannot be estimated from the available data). Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
System Organ Class Common ≥ 1/100 to < 1/10 Uncommon ≥1/1000 to <1/100 Rare ≥ 1/10000 to <1/1000 Not Known (cannot be estimated from available data) Infections and infestations pseudomembranous colitis*# Clostridium difficile colitis*, Vaginal infection* Immune System Disorders Anaphylactic shock* Anaphylactoid reaction*, Anaphylactic reaction*, Hypersensitivity* Nervous System Disorders Dysgeusia Gastrointestinal Disorders Abdominal pain, Diarrhoea Nausea, Vomiting Oesophageal ulcer*‡, Oesophagitis*‡ Hepatobiliary Disorders Jaundice* Skin and Subcutaneous Tissue Disorders Rash maculopapular, Urticaria Toxic epidermal necrolysis (TEN)*, Stevens-Johnson syndrome (SJS)*, Drug reaction with eosinophilia and systemic symptoms (DRESS)* Acute generalised exanthematous pustulosis (AGEP)*, Angioedema*, Erythema multiforme, Dermatitis exfoliative*, Dermatitis bullous*, Rash morbilliform*, Pruritus Renal and urinary disorders Acute kidney injury# Investigations Liver function test abnormal * ADR identified post-marketing.
‡ ADRs apply only to oral formulations. 4.
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit / risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Warnings:
Severe hypersensitivity reactions, including severe skin reactions such as drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and acute generalised exanthematous pustulosis (AGEP) have been reported in patients receiving clindamycin therapy.
8). Clindamycin Capsules should only be used in the treatment of serious infections. In considering the use of the product, the practitioner should bear in mind the type of infection and the potential hazard of the diarrhoea which may develop, since cases of colitis have been reported during, or even two or three weeks following, the administration of clindamycin.
Studies indicate a toxin(s) produced by clostridia (especially Clostridium difficile) is the principal direct cause of antibiotic-associated colitis. These studies also indicate that this toxigenic clostridium is usually sensitive in vitro to vancomycin.
When 125 mg to 500 mg of vancomycin are administered orally four times a day for 7 - 10 days, there is a rapid observed disappearance of the toxin from faecal samples and a coincident clinical recovery from the diarrhoea. (Where the patient is receiving cholestyramine in addition to vancomycin, consideration should be given to separating the times of administration).
Colitis is a disease which has a clinical spectrum from mild, watery diarrhoea to severe, persistent diarrhoea, leucocytosis, fever, severe abdominal cramps, which may be associated with the passage of blood and mucus. If allowed to progress, it may produce peritonitis, shock and toxic megacolon.
This may be fatal. The appearance of marked diarrhoea should be regarded as an indication that the product should be discontinued immediately. The disease is likely to follow a more severe course in older patients or patients who are debilitated.
1.
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Clindamycin in United Kingdom.
Know a brand we are missing in United Kingdom? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
Diagnosis is usually made by the recognition of the clinical symptoms, but can be substantiated by endoscopic demonstration of pseudomembranous colitis. The presence of the disease may be further confirmed by culture of the stool for Clostridium difficile on selective media and assay of the stool specimen for the toxin(s) of C.
difficile. Clostridium difficile associated diarrhoea (CDAD) has been reported with use of nearly all antibacterial agents, including clindamycin, and may range in severity from mild diarrhoea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhoea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
Precautions:
Caution should be used when prescribing Clindamycin Capsules to individuals with a history of gastro-intestinal disease, especially colitis. Periodic liver and kidney function tests should be carried out during prolonged therapy. Such monitoring is also recommended in neonates and infants.
Acute kidney injury, including acute renal failure, has been reported infrequently. 8). Prolonged administration of Clindamycin Capsules, as with any anti-infective, may result in super-infection due to organisms resistant to clindamycin.
Care should be observed in the use of Clindamycin Capsules in atopic individuals. This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.